Comparable stake leader
T. Rowe Price Investment Management, Inc.
SEC ownership of Erasca, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001761918.
Disclosed value leader
Frazier Life Sciences Management, L.P.
Comparable rows
50/50
Latest evidence
31 Mar 2026
- Public ticker
- ERAS on Nasdaq
- Parsed ownership sources
-
13D/G and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
T. Rowe Price Investment Management, Inc.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
T. Rowe Price Investment Management, Inc.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
31 Mar 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001761918
- Issuer location
- San Diego, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Erasca, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
T. Rowe Price Investment ...
Disclosed value leader
Frazier Life Sciences Man...
Comparable rows
50/50
Latest evidence
31 Mar 2026
13D/G
13F
Lead comparable stake: 6.8%
13D/G row: T. Rowe Price Investment Management, Inc.
Showing 1-8 of 50 holder rows.
Quick read
T. Rowe Price Investment Management, Inc. leads the comparable SEC ownership view at 6.8%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens T. Rowe Price Investment Management, Inc.'s linked filing trail.
Comparable ownership
Top 5
T. Rowe Price Investment Manageme...
6.8%
Venrock Healthcare Capital Partne...
5.3%
Frazier Life Sciences Public Fund...
5.3%
RTW INVESTMENTS, LP
5.2%
Logos Global Management LP
4.8%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. |
13D/G
13F
Company
|
6.8%
|
$368,453,223
21,224,264 shares
|
+$88,759,076 | 31 Mar 2026 |
| Venrock Healthcare Capital Partners III, L.P. |
13D/G
|
5.3%
|
$284,405,616
16,382,812 shares
|
$0 | 31 Mar 2026 |
| Frazier Life Sciences Public Fund, L.P. |
13D/G
|
5.3%
|
$21,355,029
15,038,753 shares
|
-$10,702,679 | 30 Jun 2025 |
| RTW INVESTMENTS, LP |
13D/G
13F
Company
|
5.2%
|
$280,488,558
16,157,175 shares
|
$0 | 31 Mar 2026 |
| Logos Global Management LP |
13F
13D/G
Company
|
4.8%
from 13D/G
|
$180,407,000
11,150,000 shares
|
— | 31 Mar 2026 |
| NOVARTIS PHARMA AG |
13D/G
|
4.4%
|
$17,107,692
12,307,692 shares
|
$0 | 31 Dec 2024 |
| Paradigm Biocapital Advisors LP |
13D/G
13F
Company
|
3.3%
|
$180,417,307
10,392,702 shares
|
-$82,744,582 | 31 Mar 2026 |
| SUVRETTA CAPITAL MANAGEMENT, LLC |
13D/G
13F
Company
|
1.1%
|
$59,631,027
3,434,967 shares
|
-$192,123,762 | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$2,283,572.
Buys
$0
Insiders: 0
Sells
$2,283,572
Insiders: 2
Net
-$2,283,572
Shares: -220,000
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 220,000
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 80,000 | $0 | $1,312,000 | -$1,312,000 |
| 3-6 | 0 | 140,000 | $0 | $971,572 | -$971,572 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-14 of 14 reporting-owner rows connected to Erasca, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
14
Largest Forms 3/4/5 holder
ARCH Venture Partners X, LLC
Net 12M change
-$2,283,572
Latest report
01 Apr 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| ARCH Venture Partners X, LLC | 10%+ Owner | $17,572,804 | Mixed | 20 Jul 2021 | ||
| Bihua Chen | Director | $17,187,655 | Mixed | 22 Jun 2023 | ||
| Wei Lin | Chief Medical Officer | $501,983 | Mixed | 01 Feb 2023 | ||
| Ebun Garner | Chief Legal Officer | $411,246 | -$1,982,812 | -83% | Filing P/S | 01 Apr 2026 |
| David M. Chacko | CFO and CBO | $334,380 | Mixed | 15 Dec 2025 | ||
| Pratik S. Multani | Director | $257,570 | Mixed | 01 Jan 2026 | ||
| Shannon Morris | Chief Medical Officer | $0 | -$300,760 | -100% | Mixed | 04 Mar 2026 |
| James Arthur Bristol | Director | Mixed | 01 Jan 2026 | |||
| Michael David Varney | Director | Mixed | 29 Jan 2026 | |||
| Valerie Denise Harding Start | Director | Mixed | 01 Jan 2026 | |||
| Jean I. Liu | Director | Mixed | 01 Jan 2026 | |||
| Julie Hambleton | Director | Mixed | 24 Jun 2025 | |||
| Jonathan E. Lim | Chairman & CEO, Director, 10%+ Owner | Mixed | 29 Jan 2026 | |||
| Alexander W. Casdin | Director | Mixed | 01 Jan 2026 |
Recent insider transactions for Erasca, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Ebun Garner | ERAS | Common Stock | Sale | -76.1% | $1,312,000 | $16.40 | -80,000 | 25,076 | 01 Apr 2026 | Direct |
| Ebun Garner | ERAS | Common Stock | Options Exercise | 319% | 80,000 | 105,076 | 01 Apr 2026 | Direct | ||
| Ebun Garner | ERAS | Stock Option (right to buy) | Options Exercise | -22.2% | -80,000 | 280,000 | 01 Apr 2026 | Direct | ||
| Shannon Morris | ERAS | Common Stock | Sale | -100% | $300,760 | $15.04 | -20,000 | 0 | 04 Mar 2026 | Direct |
| Shannon Morris | ERAS | Common Stock | Options Exercise | 20,000 | 20,000 | 04 Mar 2026 | Direct | |||
| David M. Chacko | ERAS | Stock option (right to buy) | Award | 640,000 | 640,000 | 29 Jan 2026 | Direct | |||
| Shannon Morris | ERAS | Stock option (right to buy) | Award | 625,000 | 625,000 | 29 Jan 2026 | Direct | |||
| Michael David Varney | ERAS | Stock option (right to buy) | Award | 96,000 | 96,000 | 29 Jan 2026 | Direct | |||
| Ebun Garner | ERAS | Stock option (right to buy) | Award | 560,000 | 560,000 | 29 Jan 2026 | Direct | |||
| Jonathan E. Lim | ERAS | Stock option (right to buy) | Award | 2,000,000 | 2,000,000 | 29 Jan 2026 | Direct | |||
| Ebun Garner | ERAS | Common Stock | Sale | -82.7% | $670,812 | $5.59 | -120,000 | 25,076 | 07 Jan 2026 | Direct |
| Ebun Garner | ERAS | Common Stock | Options Exercise | 478.6% | 120,000 | 145,076 | 07 Jan 2026 | Direct | ||
| James Arthur Bristol | ERAS | Stock Option (right to buy) | Award | 37,762 | 37,762 | 01 Jan 2026 | Direct | |||
| Jean I. Liu | ERAS | Stock Option (right to buy) | Award | 20,617 | 20,617 | 01 Jan 2026 | Direct | |||
| Pratik S. Multani | ERAS | Stock Option (right to buy) | Award | 19,532 | 19,532 | 01 Jan 2026 | Direct | |||
| Valerie Denise Harding Start | ERAS | Stock Option (right to buy) | Award | 24,306 | 24,306 | 01 Jan 2026 | Direct | |||
| Alexander W. Casdin | ERAS | Stock Option (right to buy) | Award | 23,872 | 23,872 | 01 Jan 2026 | Direct | |||
| David M. Chacko | ERAS | Common Stock | Other | 6.79% | 17,793 | 279,980 | 15 Dec 2025 | Direct | ||
| Ebun Garner | ERAS | Common Stock | Award | 18.4% | 3,902 | 25,076 | 15 Dec 2025 | Direct | ||
| Michael David Varney | ERAS | Stock option (right to buy) | Award | 120,000 | 120,000 | 24 Jun 2025 | Direct | |||
| Jean I. Liu | ERAS | Stock option (right to buy) | Award | 120,000 | 120,000 | 24 Jun 2025 | Direct | |||
| Julie Hambleton | ERAS | Stock option (right to buy) | Award | 120,000 | 120,000 | 24 Jun 2025 | Direct | |||
| Valerie Denise Harding Start | ERAS | Stock option (right to buy) | Award | 120,000 | 120,000 | 24 Jun 2025 | Direct | |||
| Pratik S. Multani | ERAS | Stock option (right to buy) | Award | 120,000 | 120,000 | 24 Jun 2025 | Direct | |||
| James Arthur Bristol | ERAS | Stock option (right to buy) | Award | 120,000 | 120,000 | 24 Jun 2025 | Direct | |||
| Alexander W. Casdin | ERAS | Stock option (right to buy) | Award | 120,000 | 120,000 | 24 Jun 2025 | Direct |
* marks a reported price that did not pass the local price check.